Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: The first intervention group: (Fasting mimicking diet 16/8): the people were given nutritional recommendations to control the disease and a person is in a fasting mimicking mode for 16
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years Having evidence of non-alcoholic steatohepatitis and CAP score over 263 Not having a history of alcohol and drug abuse Absence of other chronic and acute liver disorders No use of chemical and herbal medicines that affect the liver and weight Not having a chronic inflammatory disease and no history of cancer No treatment with anti-inflammatory drugs, corticosteroids and hormones Not having lost more than 8 percent of the weight in the last 6 months Blood pressure less than 140/90 mmHg Not having uncontrolled kidney disease, pituitary disorders, thyroid, cardiovascular diseases, diabetes and digestive system disorders that affect absorption No history of excessive consumption of flaxseed Not having clinically diagnosed psychiatric disorders that impair the patient's ability to provide written informed consent Willingness to participate in the study
Exclusion criteria
Exclusion criteria: Having clinically diagnosed psychiatric disorders that impair the patient's ability to provide written informed consent Use of other supplements Unwillingness to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of steatosis and liver fibrosis. Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Fibroscan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;Insulin sensitivity index. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: math formula.;Insulin resistance index. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: math formula.;Insulin concentration. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;Anthropometric indices. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: Tape measure, scale and mathematical formula.;Blood pressure. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: Sphygmomanometer.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;Liver enzymes alanine transaminase, aspartate aminotransferase,gamma-glutamyl tansferase. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;Serum glucose concentration. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;HbA1C. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzita Hekmatdoost
Shahid Beheshti University of Medical Sciences
Outcome results
None listed